7 Benefits of GLP-1 Medications Beyond Weight Loss

The SELECT trial — a landmark study of over 17,600 adults with obesity and existing cardiovascular disease — found that semaglutide 2.4mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20%. This was in patients without diabetes, meaning the heart protection is independent of blood sugar control. NEJM

This result was so significant that the FDA approved Wegovy with a cardiovascular risk reduction indication — making it the first obesity medication ever to receive this label.

In late 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. Clinical trials showed significant reductions in the apnea-hypopnea index (AHI) — the standard measure of sleep apnea severity. Many patients saw their sleep apnea improve enough to reduce or eliminate CPAP dependence. FDA

For the estimated 30 million Americans with sleep apnea, this represents a potential game-changer in treatment.

Non-alcoholic steatohepatitis (MASH, formerly NASH) is a progressive liver disease affecting tens of millions of Americans. GLP-1 medications have shown remarkable results in reducing liver fat and inflammation. Trials have demonstrated that semaglutide can resolve MASH in a significant percentage of patients and improve fibrosis staging — the key marker of liver damage progression. PubMed

One of the most exciting emerging findings: GLP-1 medications appear to reduce alcohol consumption and cravings. A 2025 study published in JAMA Psychiatry found that patients on semaglutide reported significantly lower alcohol intake. The mechanism appears to involve GLP-1 receptors in the brain's reward pathways — the same circuits involved in addiction. JAMA Psychiatry

Early research also suggests potential benefits for nicotine addiction, with active clinical trials at UNC investigating semaglutide's effects on smoking cessation.

The FLOW trial demonstrated that semaglutide reduced the risk of kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. This is particularly meaningful because kidney disease is one of the most serious long-term complications of both diabetes and obesity, and effective treatments have historically been limited. NEJM

Beyond weight loss, GLP-1 medications appear to directly reduce systemic inflammation. Researchers have documented decreases in C-reactive protein (CRP) and other inflammatory biomarkers that are independent of the weight loss itself. This anti-inflammatory effect may explain some of the cardiovascular benefits and could have implications for conditions like arthritis and inflammatory bowel disease. Nature Medicine

GLP-1 medications have shown benefits for peripheral artery disease (PAD), a condition where narrowed arteries reduce blood flow to the limbs. The cardiovascular benefits seen in the SELECT trial extended to PAD outcomes, suggesting that GLP-1 medications may help improve circulation and reduce the risk of serious complications like amputation in at-risk patients.